Evidence from the studies included in this systematic review did not demonstrate that vitamin D supplementation in adults , results in an improvement in circulating inflammatory and endothelial function biomarkers/parameters .
This systematic review does not therefore support the use of vitamin D supplementation as a therapeutic or preventative measure for CVD in this respect
This systematic review aims to evaluate r and omised controlled trials ( RCTs ) investigating the effect of vitamin D supplementation on  endothelial function and inflammation in adults .
Impact of Vitamin D Supplementation on Arterial Vasomotion, Stiffness and Endothelial Biomarkers in Chronic Kidney Disease Patients
Background Cardiovascular events are frequent and vascular endothelial function is abnormal in patients with chronic kidney disease ( CKD ) . We demonstrated endothelial dysfunction with vitamin D deficiency in CKD patients ; however the impact of cholecalciferol supplementation on vascular stiffness and vasomotor function , endothelial and bone biomarkers in CKD patients with low 25-hydroxy vitamin D [ 25(OH)D ] is unknown , which this study investigated . Methods We assessed non-diabetic patients with CKD stage 3/4 , age 17–80 years and serum 25(OH)D < 75 nmol/L.  Brachial artery Flow Mediated Dilation ( FMD ) , Pulse Wave Velocity ( PWV ) , Augmentation Index ( AI ) and circulating blood biomarkers were evaluated at baseline and at 16 weeks . Oral 300,000 units cholecalciferol was administered at baseline and 8-weeks . Results Clinical characteristics of 26 patients were : age 50±14 ( mean±1SD ) years , eGFR 41±11 ml/min/1.73 m2 , males 73 % , dyslipidaemia 36 % , smokers 23 % and hypertensives 87 % .  At 16-week serum 25(OH)D and calcium increased ( 43±16 to 84±29 nmol/L , p<0.001 and 2.37±0.09 to 2.42±0.09 mmol/L ; p = 0.004 , respectively ) and parathyroid hormone decreased ( 10.8±8.6 to 7.4±4.4 ; p = 0.001 ) . FMD improved from 3.1±3.3 % to 6.1±3.7 % , p = 0.001 . Endothelial biomarker concentrations decreased : E-Selectin from 5666±2123 to 5256±2058 pg/mL ; p = 0.032 , ICAM-1 , 3.45±0.01 to 3.10±1.04 ng/mL ; p = 0.038 and VCAM-1 , 54±33 to 42±33 ng/mL ; p = 0.006 . eGFR , BP , PWV , AI , hsCRP , von Willebr and factor and Fibroblast Growth Factor-23 , remained unchanged . Conclusion This study demonstrates for the first time improvement of endothelial vasomotor and secretory functions with vitamin D in CKD patients without significant adverse effects on arterial stiffness , serum calcium or FGF-23 . Trial Registration Clinical Trials.gov
Evidence from the studies included in this systematic review did not demonstrate that vitamin D supplementation in adults , results in an improvement in circulating inflammatory and endothelial function biomarkers/parameters .
This systematic review does not therefore support the use of vitamin D supplementation as a therapeutic or preventative measure for CVD in this respect
This systematic review aims to evaluate r and omised controlled trials ( RCTs ) investigating the effect of vitamin D supplementation on  endothelial function and inflammation in adults .